What does patisiran sodium interact with, and how is it handled in the body?
Patisiran sodium is an RNA interference (RNAi) therapy designed to lower production of a target protein. The “interaction” question usually comes up in three ways: (1) drug–drug interactions, (2) interactions with food/supplements, and (3) how patisiran’s formulation and delivery affect co-administered medicines (for example, via infusion-related premedication).
The specific interaction details (which drugs it changes, which foods/supplements matter, and the clinical management steps) depend on the approved prescribing information for patisiran sodium and its co-meds used during dosing. If you mean a particular scenario (such as another medication you take alongside patisiran), tell me the drug names and timing, and I can map them to the interaction guidance.
Are there known drug–drug interactions?
Drug–drug interaction risk for patisiran is usually discussed in terms of whether it alters metabolism/clearance of other drugs or whether other drugs change patisiran’s effectiveness or safety. Clinicians also watch for overlap with infusion reactions because patisiran dosing commonly involves premedication to reduce hypersensitivity-type events.
If you’re looking for a practical answer, the key point is: interaction guidance is tied to the specific premedication regimen and any other therapies you’re using for the same condition (for example, medicines used for hereditary transthyretin amyloidosis care). Provide your co-med list and I’ll narrow down what matters most.
Do foods, alcohol, or supplements interact with patisiran?
For many biologics and RNAi drugs administered by infusion, food-related interactions are less common than for oral small-molecule drugs. Still, supplements can matter indirectly through effects on bleeding risk, immune modulation, or liver function—depending on what else you’re taking and your comorbidities.
If you name the supplement(s) and your reason for taking them, I can help identify whether they’re typically flagged alongside patisiran in real-world medication reviews.
Does patisiran sodium interact with other transthyretin amyloidosis treatments?
In practice, patisiran may be used in a regimen that includes other disease-modifying or supportive therapies for hereditary transthyretin amyloidosis. Interactions here can be less about direct pharmacology and more about:
- shared side effects (for example, neuropathy-related symptom overlap),
- infusion scheduling/logistics,
- and cumulative liver or kidney monitoring needs.
If you tell me which additional TTR therapies you use (for example, tafamidis, vutrisiran, or others), I can focus on the interaction questions that come up for that combination.
What “interactions” are patients actually worried about?
Patients commonly mean one of these:
- allergic or infusion reactions during or after patisiran,
- interactions with corticosteroids/antihistamines used as premedication,
- and whether to adjust other medicines before appointments.
If you share what you’re taking (especially any allergy meds, blood thinners, antidepressants, or other infusion medications), I’ll translate your concern into the relevant interaction checks.
Can you share your medication list so I can answer the interaction question precisely?
“Patisiran sodium interactions” is broad. To give an accurate answer, I need:
1) the exact co-medication names (including OTCs and supplements),
2) doses if you know them,
3) when you take them relative to your patisiran infusion.
If you provide that, I’ll respond with a focused, scenario-based interaction check.